ticlopidine hydrochloride
Film Coated tablet
COMPOSITION
Each film coated tablet contains:
ticlopidine hydrochloride ..................... 250 mg
PHARMACOLOGY
The ticlopidine inhibition activity at aggregation is to suppress all platelet activity level by:
- Reducing platelet adherence.
- Inhibiting platelet aggregation.
- Inhibiting platelet granule constituents release.
- Inducing the increase of disaggregation.
INDICATION
Pathological process including thrombogenic risks in patients who can not tolerate aspirin.
DOSAGE AND ADMINISTRATION
For oral use.
Doctor's prescription should be strictly followed.
Dosage: 1 tablet, 1 or 2 times daily after meal.
WARNING AND PRECAUTIONS
- Avoid concomitant used of aspirin or anticoagulant without specific monitoring.
- Physicians or dentists should be informed that their patients is in ticlopidine therapy before surgery or tooth extraction.
- Consult the doctor if bleeding or hematoma occurs.
- Discontinue therapy in the event of fever, sore throat or mouth ulcerations. Further treatment will be decided by the physician after performing blood count evaluation.
- Avoid using ticlopidine for pregnant women, nursing mothers and children.
- Hematological evaluation should be performed periodically.
- Minor gastrointestinal disorders.
- Skin allergic reactions.
- Agranulocytosis, thrombopenia or medullary aplasia such as in cholestatic icterus with or without elevated transaminase.
- Hemopathies and hemorrhagic diathesis where bleeding time is prolonged.
- Organic lessions such as active ulcers or acute hemorrhagic strokes.
- Known hypersensitivity to ticlopidine.
- History of leukopenia, thrombopenia and agranulocytosis.
Store at 25° - 30° C
PRESENTATION
Box of 2 strips of 10 film coated tablet.
Reg. No. :DKL 9904513417A1
Manufactured by:
PT Prafa
Citeureup, Bogor-lndonesia
For:
Darya-Varia LABORATORIA
Gunung Putri, Bogor - Indonesia
0 Komentar
Penulisan markup di komentar